NAGIOS: RODERIC FUNCIONANDO

The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis

dc.contributor.author	Arnaiz, J. A.
dc.contributor.author	PEPs group
dc.contributor.author	Moltó Ruiz, María Dolores
dc.contributor.author	Balanzá Martínez, Vicent
dc.date.accessioned	2022-06-16T13:41:22Z
dc.date.available	2022-06-16T13:41:22Z
dc.date.issued	2021
dc.identifier.citation	Arnaiz, J. A. PEPs group Moltó Ruiz, María Dolores Balanzá Martínez, Vicent 2021 The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis Psychopharmacology 238 3 665 676
dc.identifier.uri	https://hdl.handle.net/10550/83192
dc.description.abstract	Introduction: The role of Olanzapine therapeutic drug monitoring is controversial. The present study explores the associations of Olanzapine plasma concentrations with clinical response and metabolic side effects in first episode psychosis (FEP) after 2 months of treatment. Methods: Forty-seven patients were included. Improvement in clinical symptomatology was assessed using the PANSS. Metabolic assessment included weight, blood pressure, waist circumference, blood glucose, total cholesterol, high-density lipoprotein, low-density lipoprotein, and triglycerides. Results: The Olanzapine plasma concentrations after 2 months of treatment were positively correlated with weight gain (r = 0.49, p = 0.003), and a concentration > 23.28 ng/mL was identified as a positive predictor of weight gain (≥ 7%). The Olanzapine concentration to dose (C/D) ratio was positively correlated with the percentage of improvement in the total PANSS (r = 0.46, p = 0.004), and a C/D ratio > 2.12 was identified as a positive predictor of a good response (percentage of improvement > 30%) after 2 months of treatment. We also identified several factors that could alter Olanzapine pharmacokinetics: gender (p = 0.03), diagnosis (p = 0.05), smoking habit (p = 0.05), and co-medications such as valproic acid (p = 0.05) and anxiolytics (p = 0.01). Discussion: In conclusion, our results suggest that therapeutic drug monitoring of Olanzapine could be helpful to evaluate therapeutic efficacy and metabolic dysfunction in FEP patients treated with Olanzapine.
dc.language.iso	eng
dc.relation.ispartof	Psychopharmacology, 2021, vol. 238, num. 3, p. 665-676
dc.subject	Farmacologia
dc.subject	Medicaments
dc.title	The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis
dc.type	journal article	es_ES
dc.date.updated	2022-06-16T13:41:22Z
dc.identifier.doi	10.1007/s00213-020-05715-5
dc.identifier.idgrec	142238
dc.rights.accessRights	open access	es_ES